scispace - formally typeset
X

Xin Zhou

Researcher at Tianjin Medical University General Hospital

Publications -  107
Citations -  3280

Xin Zhou is an academic researcher from Tianjin Medical University General Hospital. The author has contributed to research in topics: Medicine & Ventricular remodeling. The author has an hindex of 24, co-authored 91 publications receiving 2510 citations. Previous affiliations of Xin Zhou include Tianjin Medical University.

Papers
More filters
Journal ArticleDOI

Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance.

TL;DR: In this paper, the authors evaluated the efficacy of intravenous infusion of genetically modified mesenchymal stem cells (MSCs) overexpressing CXC chemokine receptor 4 (CXCR4).

Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance

TL;DR: In summary, intravenous delivery of genetically modified MSCs expressing CXCR4 may be a useful, non-invasive, and safe therapeutic strategy for post-infarction myocardial repair.
Journal ArticleDOI

Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients.

TL;DR: It is found that CHF was associated with distinct gut microbiota dysbiosis and pinpointed the specific core bacteria imbalance in CHF, along with correlations between changes in certain metabolites and gut microbes.
Journal ArticleDOI

Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction

TL;DR: These results provide the first evidence that cardiovascular outcomes post-MI are driven by intestinal microbiota translocation into systemic circulation and new therapeutic strategies targeting to protect the gut barrier and eliminate gut bacteria translocation may reduce or even prevent cardiovascular events post- MI.
Journal ArticleDOI

Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy

TL;DR: Evidence is provided for the existence of NETs in I/R-challenged myocardium and the long-term benefit of a novel DNase-based reperfusion strategy (DNase I + rt-PA) is confirmed, which might be a promising option for the treatment of myocardial I-R injury and coronary no-reflow.